Strategy opens 2026 with $116M Bitcoin purchase
Strategy has started 2026 with a $116 million Bitcoin buy despite reporting a significant unrealised loss in the previous quarter.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Strategy has started 2026 with a $116 million Bitcoin buy despite reporting a significant unrealised loss in the previous quarter.
Bank of America has approved adviser-led recommendations of spot Bitcoin ETFs across its US wealth business.
Crypto funds attracted $47.2 billion in 2025, with strong altcoin inflows offsetting a sharp slowdown in Bitcoin demand.
New research cited by an ESG expert challenges long-held claims about Bitcoin mining’s environmental and energy impact.
Drake has been named in a RICO lawsuit accusing him of using crypto casino Stake to hide payments linked to music botting.
Goldman Sachs has upgraded Coinbase on stronger product momentum while cutting its outlook for rival trading platform eToro.
Polymarket has teamed up with Parcl to bring housing price indexes into prediction markets for the first time.
Jollibee Foods Corp. shares saw their largest single-day rally in 18 years on Tuesday after the Philippine fast-food giant announced a transformative plan to spin off its international business and list it on a U.S. stock exchange.
The move is designed to decouple the company’s high-growth global brands from its stable, cash-generative domestic operations, providing investors with "targeted exposure" to two distinct equity stories.
Advanced Micro Devices (NASDAQ:AMD) introduced a sweeping new portfolio of x86 processors at CES 2026, targeting the burgeoning "physical AI" market.
The new Ryzen AI Embedded P100 and X100 series are designed to bring high-performance, low-latency intelligence to automotive cockpits, industrial robotics, and autonomous systems, moving complex decision-making from the cloud to the device itself.
Moderna (NASDAQ:MRNA) officially moved to challenge the multi-billion-dollar seasonal influenza market today, submitting marketing authorization applications for its investigational vaccine, mRNA-1010, to regulators in the U.S., Europe, Canada, and Australia.
UMH Properties (NYSE:UMH) reported a transformative 2025 in its preliminary year-end update, fueled by a record expansion of its rental portfolio and a comprehensive refinancing of its debt stack.
Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, today announced positive topline results from the Phase 3 INDIGO registrational trial evaluating obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD).
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade